Raymond Evers

14.9k total citations · 3 hit papers
99 papers, 9.2k citations indexed

About

Raymond Evers is a scholar working on Oncology, Pediatrics, Perinatology and Child Health and Pharmacology. According to data from OpenAlex, Raymond Evers has authored 99 papers receiving a total of 9.2k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Oncology, 40 papers in Pediatrics, Perinatology and Child Health and 33 papers in Pharmacology. Recurrent topics in Raymond Evers's work include Drug Transport and Resistance Mechanisms (59 papers), Pharmacological Effects and Toxicity Studies (38 papers) and Pharmacogenetics and Drug Metabolism (29 papers). Raymond Evers is often cited by papers focused on Drug Transport and Resistance Mechanisms (59 papers), Pharmacological Effects and Toxicity Studies (38 papers) and Pharmacogenetics and Drug Metabolism (29 papers). Raymond Evers collaborates with scholars based in United States, Netherlands and Germany. Raymond Evers's co-authors include Piet Borst, Marcel Kool, Jan Wijnholds, Xiaoyan Chu, Liesbeth van Deemter, Kelly Bleasby, Balázs Sarkadi, Éva Bakos, Alfred H. Schinkel and András Váradi and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Raymond Evers

98 papers receiving 8.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Family of Drug Transporters: the Multidrug Resistance-Associated Proteins

2000 1.4k citations Piet Borst, Raymond Evers et al. JNCI Journal of the National Cancer Institute profile →
Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA.

1998 529 citations Raymond Evers, Marcel Kool et al. Journal of Clinical Investigation profile →
The multidrug resistance protein family

1999 525 citations Piet Borst, Raymond Evers et al. Biochimica et Biophysica Acta (BBA) - Biomembranes profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Raymond Evers United States	52	5.8k	2.8k	2.7k	1.8k	1.0k	99	9.2k
Jörg König Germany	55	8.1k 1.4×	2.3k 0.8×	4.2k 1.5×	1.9k 1.1×	1.8k 1.7×	128	10.9k
Anne T. Nies Germany	44	5.1k 0.9×	2.0k 0.7×	2.4k 0.9×	1.1k 0.6×	1.2k 1.2×	91	7.3k
Liesbeth van Deemter Netherlands	23	7.1k 1.2×	2.6k 0.9×	3.7k 1.3×	900 0.5×	1.5k 1.4×	24	9.1k
Els Wagenaar Netherlands	53	10.1k 1.7×	4.3k 1.6×	5.0k 1.8×	1.8k 1.0×	1.8k 1.7×	97	14.1k
Elke Schaeffeler Germany	52	3.3k 0.6×	2.8k 1.0×	2.0k 0.7×	1.8k 1.0×	1.4k 1.3×	181	9.6k
Carla A.A.M. Mol Netherlands	16	6.1k 1.0×	1.7k 0.6×	3.3k 1.2×	806 0.5×	1.4k 1.3×	16	7.8k
Gabriele Jedlitschky Germany	50	5.1k 0.9×	2.1k 0.7×	2.4k 0.9×	683 0.4×	1.2k 1.2×	104	7.4k
I Pastan United States	29	8.4k 1.4×	4.7k 1.7×	2.6k 1.0×	974 0.6×	1.5k 1.4×	48	10.8k
Toshihisa Ishikawa Japan	47	4.4k 0.8×	3.1k 1.1×	1.5k 0.5×	734 0.4×	844 0.8×	156	7.7k
George L. Scheffer Netherlands	62	10.5k 1.8×	5.3k 1.9×	4.1k 1.5×	1.1k 0.6×	2.7k 2.5×	141	14.9k

Countries citing papers authored by Raymond Evers

Since Specialization

Citations

This map shows the geographic impact of Raymond Evers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raymond Evers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raymond Evers more than expected).

Fields of papers citing papers by Raymond Evers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raymond Evers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raymond Evers. The network helps show where Raymond Evers may publish in the future.

Co-authorship network of co-authors of Raymond Evers

This figure shows the co-authorship network connecting the top 25 collaborators of Raymond Evers. A scholar is included among the top collaborators of Raymond Evers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raymond Evers. Raymond Evers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nicolaï, Johan, et al.. (2025). Toward improved clearance predictions and distribution profiles employing the isolated perfused rat liver model: Experimental optimization. Drug Metabolism and Disposition. 53(3). 100045–100045.

Liang, Xiaomin, et al.. (2023). Toward improved predictions of pharmacokinetics of transported drugs in hepatic impairment: Insights from the extended clearance model. CPT Pharmacometrics & Systems Pharmacology. 13(1). 118–131. 2 indexed citations

Liang, Xiaomin, et al.. (2022). Predicting changes in the pharmacokinetics of CYP3A‐metabolized drugs in hepatic impairment and insights into factors driving these changes. CPT Pharmacometrics & Systems Pharmacology. 12(2). 261–273. 10 indexed citations

Hafey, Michael J., Robert Houle, Keith Q. Tanis, et al.. (2020). A Two-Tiered In Vitro Approach to De-Risk Drug Candidates for Potential Bile Salt Export Pump Inhibition Liabilities in Drug Discovery. Drug Metabolism and Disposition. 48(11). 1147–1160. 14 indexed citations

Billington, Sarah, Laurent Salphati, Cornelis E. C. A. Hop, et al.. (2019). Interindividual and Regional Variability in Drug Transporter Abundance at the Human Blood–Brain Barrier Measured by Quantitative Targeted Proteomics. Clinical Pharmacology & Therapeutics. 106(1). 228–237. 60 indexed citations

Prasad, Bhagwat, Andrea Gaedigk, Marc Vrana, et al.. (2016). Ontogeny of Hepatic Drug Transporters as Quantified by LC‐MS/MS Proteomics. Clinical Pharmacology & Therapeutics. 100(4). 362–370. 113 indexed citations

Chu, Xiaoyan, John R. Strauss, Jing Li, et al.. (2006). Characterization of Mice Lacking the Multidrug Resistance Protein Mrp2 (Abcc2). Journal of Pharmacology and Experimental Therapeutics. 317(2). 579–589. 105 indexed citations

Hartley, Dylan P., Xudong Dai, Jocelyn Yabut, et al.. (2006). Identification of potential pharmacological and toxicological targets differentiating structural analogs by a combination of transcriptional profiling and promoter analysis in LS-180 and Caco-2 adenocarcinoma cell lines. Pharmacogenetics and Genomics. 16(8). 579–599. 30 indexed citations

Chu, Xiaoyan, et al.. (2004). Transport of Ethinylestradiol Glucuronide and Ethinylestradiol Sulfate by the Multidrug Resistance Proteins MRP1, MRP2, and MRP3. Journal of Pharmacology and Experimental Therapeutics. 309(1). 156–164. 80 indexed citations

10.

Holló, Zsolt, András Kern, Éva Bakos, et al.. (2002). Role of the N-terminal Transmembrane Region of the Multidrug Resistance Protein MRP2 in Routing to the Apical Membrane in MDCKII Cells. Journal of Biological Chemistry. 277(34). 31048–31055. 60 indexed citations

11.

Bakos, Éva, Raymond Evers, Giulia Calenda, et al.. (2000). Characterization of the amino-terminal regions in the human multidrug resistance protein (MRP1). Journal of Cell Science. 113(24). 4451–4461. 94 indexed citations

12.

Borst, Piet, Raymond Evers, Marcel Kool, & Jan Wijnholds. (2000). A Family of Drug Transporters: the Multidrug Resistance-Associated Proteins. JNCI Journal of the National Cancer Institute. 92(16). 1295–1302. 1386 indexed citations breakdown →

13.

Bakos, Éva, et al.. (2000). Interactions of the Human Multidrug Resistance Proteins MRP1 and MRP2 with Organic Anions. Molecular Pharmacology. 57(4). 760–768. 269 indexed citations

14.

Raggers, René J., Ardy van Helvoort, Raymond Evers, & Gerrit van Meer. (1999). The human multidrug resistance protein MRP1 translocates sphingolipid analogs across the plasma membrane. Journal of Cell Science. 112(3). 415–422. 129 indexed citations

15.

Borst, Piet, Raymond Evers, Marcel Kool, & Jan Wijnholds. (1999). The multidrug resistance protein family. Biochimica et Biophysica Acta (BBA) - Biomembranes. 1461(2). 347–357. 525 indexed citations breakdown →

16.

Bakos, Éva, Raymond Evers, Gergely Szakács, et al.. (1998). Functional Multidrug Resistance Protein (MRP1) Lacking the N-terminal Transmembrane Domain. Journal of Biological Chemistry. 273(48). 32167–32175. 270 indexed citations

17.

Wijnholds, Jan, Raymond Evers, Carla A.A.M. Mol, et al.. (1997). Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nature Medicine. 3(11). 1275–1279. 364 indexed citations

18.

Borst, Piet, Marcel Kool, & Raymond Evers. (1997). Do cMOAT (MRP2), other MRP homologues, and LRP play a role in MDR?. Seminars in Cancer Biology. 8(3). 205–213. 71 indexed citations

19.

Zaman, Guido J.R., Nicole H.P. Cnubben, Peter J. van Bladeren, Raymond Evers, & Piet Borst. (1996). Transport of the glutathione conjugate of ethacrynic acid by the human multidrug resistance protein MRP. FEBS Letters. 391(1-2). 126–130. 65 indexed citations

20.

Evers, Raymond, Guido J.R. Zaman, Liesbeth van Deemter, et al.. (1996). Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells.. Journal of Clinical Investigation. 97(5). 1211–1218. 224 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact